Chuen-Yen Lau1, Andrew D Mihalek2,3,4, Jing Wang5, Lori E Dodd6, Katie Perkins7,8, Susan Price7, Sharon Webster7, Stefania Pittaluga9, Les R Folio10, V Koneti Rao7, Kenneth N Olivier2. 1. 1 Collaborative Clinical Research Branch, Division of Clinical Research. 2. 3 Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 3. 2 Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia; and. 4. 4 Lovelace Respiratory Research Institute, Albuquerque, New Mexico. 5. 5 Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., and. 6. 6 Biostatistics Research Branch, Division of Clinical Research, and. 7. 7 Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 8. 8 Leidos Biomedical Research, Inc., Frederick National Laboratory, National Cancer Institute, National Institutes of Health, Frederick, Maryland. 9. 9 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 10. 10 Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Abstract
RATIONALE: Patients with autoimmune lymphoproliferative syndrome (ALPS), a disorder of impaired lymphocyte apoptosis, often undergo radiographic chest imaging to evaluate the presence and progression of lymphadenopathy. These images often lead to parenchymal and interstitial lung findings of unclear clinical significance. OBJECTIVES: To characterize the pulmonary findings associated with ALPS and to determine if lung abnormalities present on computed tomographic (CT) imaging of the chest correlate with infection or functional status. METHODS: Patients with lung abnormalities observed on chest CT scans were retrospectively identified from the largest known ALPS cohort. Lung computed tomography findings were characterized and correlated with medical records, bronchoalveolar lavage, biopsy, and lung function. MEASUREMENTS AND MAIN RESULTS: CT images of the chest were available for 234 (92%) of 255 of the patients with ALPS. Among patients with a chest CT scan, 18 (8%) had lung abnormalities on at least one CT scan. Fourteen (78%) of those 18 were classified as having ALPS with undetermined genetic defect. Most patients (n = 16 [89%]) with lung lesions were asymptomatic. However, two (11%) of them had associated dyspnea and/or desaturation on room air. Immunosuppressive treatment was administered for lung disease in nine (50%) cases, and all were followed for clinical outcomes. CONCLUSIONS: Patients with ALPS can develop chest radiographic findings with protean manifestations that may mimic pulmonary infection. Management of patients with ALPS with incidental lung lesions identified by CT imaging should be guided by clinical correlation. Symptomatic patients may benefit from chest CT imaging and lesion biopsy to exclude infection and guide administration of immunosuppressive therapy.
RATIONALE: Patients with autoimmune lymphoproliferative syndrome (ALPS), a disorder of impaired lymphocyte apoptosis, often undergo radiographic chest imaging to evaluate the presence and progression of lymphadenopathy. These images often lead to parenchymal and interstitial lung findings of unclear clinical significance. OBJECTIVES: To characterize the pulmonary findings associated with ALPS and to determine if lung abnormalities present on computed tomographic (CT) imaging of the chest correlate with infection or functional status. METHODS:Patients with lung abnormalities observed on chest CT scans were retrospectively identified from the largest known ALPS cohort. Lung computed tomography findings were characterized and correlated with medical records, bronchoalveolar lavage, biopsy, and lung function. MEASUREMENTS AND MAIN RESULTS: CT images of the chest were available for 234 (92%) of 255 of the patients with ALPS. Among patients with a chest CT scan, 18 (8%) had lung abnormalities on at least one CT scan. Fourteen (78%) of those 18 were classified as having ALPS with undetermined genetic defect. Most patients (n = 16 [89%]) with lung lesions were asymptomatic. However, two (11%) of them had associated dyspnea and/or desaturation on room air. Immunosuppressive treatment was administered for lung disease in nine (50%) cases, and all were followed for clinical outcomes. CONCLUSIONS:Patients with ALPS can develop chest radiographic findings with protean manifestations that may mimic pulmonary infection. Management of patients with ALPS with incidental lung lesions identified by CT imaging should be guided by clinical correlation. Symptomatic patients may benefit from chest CT imaging and lesion biopsy to exclude infection and guide administration of immunosuppressive therapy.
Entities:
Keywords:
imaging; natural history; pulmonary function
Authors: Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao Journal: Blood Date: 2010-06-10 Impact factor: 22.113
Authors: L J Maarschalk-Ellerbroek; P A de Jong; J M van Montfrans; J W J Lammers; A C Bloem; A I M Hoepelman; P M Ellerbroek Journal: J Clin Immunol Date: 2014-06-21 Impact factor: 8.317
Authors: Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo Journal: Blood Date: 2014-01-07 Impact factor: 22.113
Authors: A Rensing-Ehl; K Warnatz; S Fuchs; M Schlesier; U Salzer; R Draeger; I Bondzio; Y Joos; A Janda; M Gomes; M Abinun; S Hambleton; A Cant; F Shackley; T Flood; C Waruiru; K Beutel; K Siepermann; G Dueckers; T Niehues; T Wiesel; V Schuster; M G Seidel; M Minkov; K Sirkiä; M V Kopp; M Korhonen; K Schwarz; S Ehl; C Speckmann Journal: Clin Immunol Date: 2010-09-15 Impact factor: 3.969
Authors: Joshua D Milner; Tiphanie P Vogel; Lisa Forbes; Chi A Ma; Asbjørg Stray-Pedersen; Julie E Niemela; Jonathan J Lyons; Karin R Engelhardt; Yu Zhang; Nermina Topcagic; Elisha D O Roberson; Helen Matthews; James W Verbsky; Trivikram Dasu; Alexander Vargas-Hernandez; Nidhy Varghese; Kenneth L McClain; Lina B Karam; Karen Nahmod; George Makedonas; Emily M Mace; Hanne S Sorte; Gøri Perminow; V Koneti Rao; Michael P O'Connell; Susan Price; Helen C Su; Morgan Butrick; Joshua McElwee; Jason D Hughes; Joseph Willet; David Swan; Yaobo Xu; Mauro Santibanez-Koref; Voytek Slowik; Darrell L Dinwiddie; Christina E Ciaccio; Carol J Saunders; Seth Septer; Stephen F Kingsmore; Andrew J White; Andrew J Cant; Sophie Hambleton; Megan A Cooper Journal: Blood Date: 2014-10-30 Impact factor: 22.113
Authors: Marcus P Kennedy; Peadar G Noone; Margaret W Leigh; Maimoona A Zariwala; Susan L Minnix; Michael R Knowles; Paul L Molina Journal: AJR Am J Roentgenol Date: 2007-05 Impact factor: 3.959
Authors: Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel Journal: Nat Immunol Date: 2013-10-28 Impact factor: 25.606
Authors: Laura Gámez-Díaz; Dietrich August; Polina Stepensky; Shoshana Revel-Vilk; Markus G Seidel; Mitsuiki Noriko; Tomohiro Morio; Austen J J Worth; Jacob Blessing; Frank Van de Veerdonk; Tobias Feuchtinger; Maria Kanariou; Annette Schmitt-Graeff; Sophie Jung; Suranjith Seneviratne; Siobhan Burns; Bernd H Belohradsky; Nima Rezaei; Shahrzad Bakhtiar; Carsten Speckmann; Michael Jordan; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2016-01 Impact factor: 10.793
Authors: Daniel Korenfeld; Kate Roussak; Sabrina Dinkel; Tiphanie P Vogel; Henry Pollack; Joseph Levy; Jennifer W Leiding; Joshua Milner; Megan Cooper; Eynav Klechevsky Journal: J Immunol Date: 2021-10-15 Impact factor: 5.422